Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective

References

• Hoyert D, Hu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2011;61:1-65
   Google Scholar
• Morbidity and mortality: 2012 chart book on cardiovascular, lung, and blood diseases. US Department of Health and Human Services: National Heart Lung and Blood Institute, 2012. Bethesda, MD. http://www.nhlbi.nih.gov/resources/docs/2012_ChartBook_508.pdf. Accessed November 19, 2012
   Google Scholar
• Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933–44
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Health Care Financing Review: Medicare & Medicaid Statistical Supplement. Table 5.5: Discharges, total days of care, and program payments for medicare beneficiaries discharged from short-stay hospitals, by principal diagnoses within Major Diagnostic Classifications (MDCs): Calendar Year 2006. Baltimore, MD: Centers for Medicare and Medicaid Services, 2005. http://www.cms.hhs.gov/MedicareMedic- aidStatSupp/downloads/2007Table5.5b.pdf. Accessed November 12, 2012
   Google Scholar
• Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74
   PubMed Web of Science ®Google Scholar
• Kuklina EV, Shaw KM, Hong Y, et al. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol — United States, 1999–2002 and 2005—200. MMWR 2011;60:109-14
   Google Scholar
• Grundy SM. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81
   PubMed Web of Science ®Google Scholar
• Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Faergeman O, Hill L, Windler E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology 2008;111:219-28
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• New patient treatment patterns, dispensing fees and rebate amounts. Data on file. AstraZeneca LP, 2012
   Google Scholar
• PHC Step Therapy Criteria: Statins. Physicians Health Choice. http://www.phccares.com/pdf/PHC%20Step%20Therapy%20Criteria%20Statins.pdf. Accessed November 19, 2012
   Google Scholar
• Step therapy program. Medical Health Associates Health Plans, 2012. http://www.mahealthcare.com/step_therapy/StepTherapy_MedAssoc_2011.pdf. Accessed November 28, 2012
   Google Scholar
• Prior Therapy Timeline Standardization: Oct – Dec 2012. Optima Health, 2012. Available at: http://public.optimahealth.com/Lists/OptimaFormsLibrary/form-doc-timeline-for-step-edit-drugs.pdf. Accessed November 19, 2012
   Google Scholar
• Ito MK, Lin JC, Morreale AP, et al. Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol. Am J Health Syst Pharm 2001;58:1734-9
   PubMed Web of Science ®Google Scholar
• Moisan J, Vaillancourt R, Grégoire JP, et al. Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes. Am J Health Syst Pharm 1999;56:1437-41
   Google Scholar
• Taylor AJ, Grace K, Swiecki J, et al. Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. Pharmacotherapy 2001;21:1130-9
   PubMed Web of Science ®Google Scholar
• Meissner B, Dickson M, Shinogle J, et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a ministate managed Medicaid organization. J Manag Care Pharm 2006;12:331-40
   PubMed Web of Science ®Google Scholar
• Ara R, Pandor A, Stevens J, et al. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Eur J Prev Cardiol 2012;19:473-83
   Google Scholar
• XE Universal Currency Converter. Mid-market exchange rates. 2013. www.xe.com. Accessed January 8, 2013
   Google Scholar
• Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. JAMA 2009;302:2104-10
   PubMed Web of Science ®Google Scholar
• Gandhi SK, Järbrink K, Fox KM, et al. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Curr Med Res Opin 2009;25:2817-28
   PubMed Web of Science ®Google Scholar
• Willey VJ, Bullano MF, Shoetan NN, et al. Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Curr Med Res Opin 2010;26:121-8
   PubMed Web of Science ®Google Scholar
• Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9
   PubMed Web of Science ®Google Scholar
• Data on file. AstraZeneca LP, 2013
   Google Scholar
• Yale Health Pharmacy Benefit for Managerial & Professional and Faculty. New Haven, CT: Yale Health, 2013; http://yalehealth.yale.edu/yale-health-pharmacy-benefit-managerial-professional-and-faculty. Accessed January 3, 2013
   Google Scholar
• Centers for Medicare and Medicaid Services. Physician Fee Schedule. Baltimore, MD: Centers for Medicare and Medicaid Services, 2012. www.cms.gov. Accessed June 12, 2012
   Google Scholar
• Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule. Baltimore, MD: Centers for Medicare and Medicaid Services, 2012. www.cms.gov. Accessed June 12, 2012
   Google Scholar
• Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160, iii-iv
   Web of Science ®Google Scholar
• Charland SL, Cziraky MJ, Quimbo R, et al. Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. J Clin Lipidol 2008;2:343-53
   Google Scholar
• Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ 2010;13:428-37
   PubMedGoogle Scholar
• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 2012;125:e2-e220
   PubMed Web of Science ®Google Scholar
• Rublee DA, Burke JP. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad Med 2010;122:16-24
   PubMed Web of Science ®Google Scholar
• Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-80
   PubMed Web of Science ®Google Scholar
• Huse DM, Song X, Ozminkowski RJ, et al. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis. Clin Ther 2006;28:1425-42
   PubMed Web of Science ®Google Scholar